xoma desperates for money during the biotech craze.
PDLI, much less future than xoma, except for ideal future on genomics (like everybody, but AFFX, no products), and at $200 a share the market cap of $3B! (xoma should go 9x6 to $54 following the same market perception).
It is a low tier deal considering xoma's prospects are so good, so near, and so real. Baxter and DNA deals should be able to get the company across one year cash, now xeoperson wants two year cash!
He does not want a "surprise" at the FDA, cash first.
Many predicted the biotech boom, but not the date and time.
But xoma does not have any genomics, maybe they should called xoma a proteomics company (the next craze building up), bpi, hu1124, geminmune, and fusion and even thaumatin are proteins! |
